Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 225Uterine Cervical Neoplasms 181Fallopian Tube Neoplasms 93Carcinoma, Ovarian Epithelial 85Endometrial Neoplasms 74Neoplasms 37Uterine Cervical Dysplasia 35Papillomavirus Infections 35Breast Neoplasms 26Peritoneal Neoplasms 25Vulvar Neoplasms 23Condylomata Acuminata 22Vaginal Neoplasms 18Recurrence 16Testicular Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 12Brenner Tumor 12Primary Myelofibrosis 11Multiple Myeloma 11Lymphoma, Non-Hodgkin 11Lymphoma, Mantle-Cell 11Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Chronic-Phase 11Leukemia, Myeloid, Accelerated Phase 11Leukemia, Lymphocytic, Chronic, B-Cell 11Blast Crisis 11

Interventions

human papillomavirus vaccine, L1 type 16, 18 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Human Papillomavirus-Related Cervical Carcinoma × Gynecologic × Clear all
NCT03728881 2025-08-03

PRIMAVERA

National Cancer Institute (NCI)

Phase 3 Completed
1,240 enrolled 107 charts
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡